Is NGNE stock safe? | Glauxie AI

Q: Is NGNE stock safe?

Neurogene Inc. (NGNE) operates in the Biotechnology industry (Healthcare sector). The company is led by CEO Rachel L. McMinn. Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy... Employees: 131.

Q: What are the risks of investing in NGNE?

Identify key risks of investing in NGNE — debt, competition, volatility, and sector headwinds.

Q: Is NGNE a good long-term investment?

Evaluate NGNE as a long-term investment using fundamental scores, growth metrics, and risk assessment.

Q: How much debt does NGNE have?

Review NGNE total debt, debt-to-equity ratio, interest coverage, and leverage trends.

Is NGNE stock safe?

🦉

Neurogene Inc. (NGNE)

Company Overview

Sector / IndustryHealthcare / Biotechnology

CEORachel L. McMinn

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5...

Key Executives

Name	Title
Andrew E. Mulberg FAAP	Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control
Arvind Sreedharan	Senior Vice President of Business Operations
Christina Shafer	Chief Commercial Officer
Christine Mikail Cvijic	President, CFO & Director
Donna Cochener-Metcalfe	Senior Vice President, General Counsel & Corporate Secretary
Julie Jordan	Chief Medical Officer

Financial Health

Risk Assessment

Weather Score0/100

RegimeN/A

NGNE Profile Financials

What are the risks of investing in NGNE? Is NGNE a good long-term investment? How much debt does NGNE have?